Q-omics provides the consensus-scored PPM1K profile across patient tissues and cancer cell-line models. PPM1K expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PPM1K is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PPM1K protein abundance shows 24,884 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where PPM1K shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPM1K — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPM1K survival associations across molecular data types. PPM1K RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPM1K RNA expression–survival associations across cancer types. High PPM1K expression shows unfavorable associations in UVM and UCEC, but favorable associations in SKCM, HNSC, LUAD and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PPM1K RNA expression.
This table summarizes PPM1K tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PPM1K. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPM1K shows lower tumor expression in KIRC, BLCA, KICH, KIRP, LUAD and UCEC. The KIRC box plot shows higher PPM1K RNA expression in normal versus tumor tissue (log2 FC = −1.269, t-test p < 0.001).
This table shows molecular features associated with PPM1K in patient tissues and cancer cell lines. In patient samples, PPM1K shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PPM1K RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
